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Abstract
The natural cytotoxic receptors (NCRs) are a unique set of activating proteins expressed mainly on the surface of natural
killer (NK) cells. The NCRs, which include three members; NKp46, NKp44 and NKp30, are critically involved in NK cytotoxicity
against different targets, including a wide range of tumor cells derived from various origins. Even though the tumor ligands
of the NCRs have not been identified yet, the selective manner by which these receptors target tumor cells may provide an
excellent basis for the development of novel anti-tumor therapies. To test the potential use of the NCRs as anti-tumor
agents, we generated soluble NCR-Ig fusion proteins in which the constant region of human IgG1 was fused to the
extracellular portion of the receptor. We demonstrate, using two different human prostate cancer cell lines, that treatment
with NKp30-Ig, dramatically inhibits tumor growth in vivo. Activated macrophages were shown to mediate an ADCC
response against the NKp30-Ig coated prostate cell lines. Finally, the Ig fusion proteins were also demonstrated to
discriminate between benign prostate hyperplasia and prostate cancer. This may provide a novel diagnostic modality in the
difficult task of differentiating between these highly common pathological conditions.
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Introduction
Immune mechanisms are thought to provide essential protec-
tion from the development of cancer diseases. Studies of human
patients and mice models have shown that deficiencies in key
immunologic components lead to increased susceptibility to the
development of cancer [1–3]. Natural killer (NK) cells are an
important subset of cytotoxic lymphocytes that belong to the
innate immune response and are best characterized by their ability
to spontaneously kill virally infected and tumor cells [4]. The
efficiency by which NK cells destroy a wide range of cell lines
suggests an important role in immunosurveillance. Indeed,
accumulating clinical and experimental data demonstrate the
importance of NK activity in cancer elimination in vivo; in mice,
depletion of NK cells results in a significantly increased
susceptibility to chemically induced cancer [1], while in leukemia
patients reduced NK cytotoxicity was shown to strictly correlate
with enhanced progression of the disease [5].
The activation of NK cells is regulated by a set of surface
receptors that either induce or inhibit the cytotoxic response [4,6].
The main mechanism that controls NK inhibition is based on the
recognition of MHC class I molecules by NK inhibitory receptors,
such as the killer-Ig-like receptors (KIRs) and the CD94/NKG2A
complex. This mechanism ensures that the NK cells are
continuously inhibited from killing healthy cells that express
normal levels of MHC class I proteins [7]. However, while MHC
class I expression is essential in order to inhibit NK cytotoxicity,
down-regulation is not enough to induce a response, as specific
activation signals are also required. These signals are delivered by
a set of lysis receptors that recognize non-MHC class I ligands,
expressed on target cells [8]. Thus, NK cells are not only capable
of sensing the absence of MHC class I proteins, but are also
equipped with surface receptors that allow specific detection of
their targets.
The main NK activating receptors involved in recognition and
killing of tumors include the NKG2D homodimer and the three
natural cytotoxic receptors (NCRs) NKp46, NKp44 and NKp30
[8]. The relative contribution of each of these receptors to NK
cytotoxicity against tumors differs, indicating the existence of
various specific lysis ligands [9]. Indeed, several stress inducible
cellular proteins have been identified as ligands for the NKG2D
receptor: the MHC class I chain related antigens (MICA and
MICB) and the UL16 binding proteins (ULBP1-4) [10].
In contrast to the NKG2D, the cellular ligands of the NCRs are
currently unknown and the only NCRs ligands identified so far are
virally derived proteins [11–14]. However, substantial evidence
indicates that cellular ligands for the NCRs do exist and that their
expression is critical for the ability of NK cells to destroy tumors
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[9,15–17]. These findings are supported by clinical studies
showing for several cases of AML a correlation between low
levels of NCRs ligands in AML patients and a poor prognosis of
the disease [18]. Furthermore, we have recently shown that
deletion of a single NCR gene, the NKp46 mouse homologue
(NCR1), significantly reduces the ability of NK cells to clear tumor
cells in vivo [19].
In the past decade, cancer immunotherapy studies have
extensively focused on the attempt to exploit the highly specific
nature of the adaptive immune response for the development of
novel treatments. This approach led to the generation of several
humanized antibodies directed against specific tumor antigens.
The impressive clinical success of the antibody-based therapy
opened the gate for an intensive search for additional highly
specific tumor markers and since 1995 several antibodies have
been approved for clinical use while more are currently being
evaluated in oncology trials [20,21].
To expand this method, various tools have been applied in an
attempt to identify new tumor antigens that would be suitable for a
wider range of cancers and still retain selective recognition. The
NCRs represent a unique example for proteins that have acquired
such a broad specificity and are highly adapted to recognize
cancer cells. To translate this potential into a therapeutic tool, we
have generated immunoglobulin (Ig) fusion proteins that contain
the extracellular portion of the receptor fused to the constant
region of human IgG1. Thus, similar to the antibody-based tumor
therapy approach, we hypothesized the NCR-Ig fusion proteins
may be used as ‘targeted missiles’; the extracellular portion
provides tumor specificity while the constant region of the human
IgG1 (Fc) allows recruitment of immune components, which
enhance specific tumor elimination. Here we show the potential
use of such therapy using human prostate cancers models.
Materials and Methods
Cells
We used the human prostate cancer cell line DU145 and the
human prostate cancer cell line PC3/Luc, which was prepared as
described before [14]. Briefly, PC3.38, a clone of the human
prostate adenocarcinoma cell line, derived from PC3 (ATCC,
CRL-1435), was infected with recombinant rLNC/Luc retrovirus
(expressing luciferase gene downstream to CMV promoter) and
selected by G418 (400 mg/ml) generating PC3/Luc clone. Stable
expression of luciferase in cell culture was routinely confirmed
using the CCCD camera.
Fusion proteins and flow cytometry analysis
The production of NKp30-Ig, NKp46D2-Ig, NKp46D1-Ig and
CD99-Ig was described before [13]. Control human IgG1 protein
(hIgG1 kappa, PHP010) was purchased from Serotec (Oxford,
UK).
Immunohistochemistry
Prostatic tissues, both hyperplasic and malignant, were fixed in
buffered formalin. Microwave heating of the formalin-fixed,
paraffin embedded tissue sections in citrate buffer was performed
to retrieve antigens. Sections were then stained by the different
NCR-Igs or control-Ig (8 mg/ml, final concentration) followed by
biotinylated-goat-anti-human-Fc (Jackson ImmunoResearch, West
Grove, PA). For detection, the avidin-biotin peroxidase complex
method was employed with Vectastain kit (Vector Laboratories,
Burlingame, CA). Staining was graded as the percentage of
positive prostatic cells (hyperplasic or malignant) from a total of
100 cells. We also evaluated the intensity of the staining as 0 =non,
1 =weak, 2 =moderate and 3= strong. Stained sections were
analyzed by two pathologists. Immunohistochemical results were
considered as positive whenever the percentage of positively
stained prostatic cells surpassed 50% and the intensity was higher
than 1.
Tumor implantation and treatment
For the DU145 model we s.c. injected male nude mice with the
human prostate tumor line DU145 (46106). Two weeks after
injection when the tumors became visible, mice were treated with
NKp30-Ig, NKp46D2-Ig, control human IgG1 or PBS. Treat-
ments were administered 5 times (days 2, 7, 15, 25 and 34) and
included an initial larger dose of the proteins (20mg/kg) followed
by lower doses (10mg/kg). Tumor progression was evaluated every
three days by measuring the diameter of the tumors.
For the PC3/Luc model, male nude mice (4–8 weeks old) were
injected with 156106 PC3/Luc cells into the s.c. space of the left
flank of each mouse. Three weeks after tumor implantation, mice
were injected i.p. with 4 mg/kg of NKp30-Ig, NKp46D2-Ig,
control human IgG1 or PBS every other day over a period of 3-4
weeks.
Imaging of tumor PC3/Luc xenografts
All mice were monitored for tumor expression before and at the
end of the treatment procedures. Only those mice that within 21
days from injection expressed a detectable size of tumor, as
evaluated by the CCCD camera, were chosen for further
manipulations. Before imaging, mice were anesthetized with 4%
chloral hydrate (Fluka-Sigma, Israel). Five minutes prior to
imaging, mice were injected i.p. with 126mg/kg body weight of
aqueous solution of Beetle lucifering (Promega Corp., Madison,
WI). The mice were then placed in a light-tight chamber of a
CCCD camera system (Roper Scientific, Princeton Instrument,
Trenton NJ) and photographed first with a supplemented
controlled light in order to take a gray-scale body reference
image. Photons emitted from the mouse were then detected in
complete darkness, collected and integrated for a period of 2 min.
A pseudo color image represents light intensity (blue as the least
intense and red as the most intense). Measurements are an
integration of the total sum of signals detected, subtracted by the
background integrated light emitted from an equal area in the
same mouse.
Pharmacokinetic analysis in vivo
Female CB17.SCID mice were injected i.p. with a single dose
(5mg/kg body weight) of NKp46D2-Ig or NKp30-Ig. Levels of
fusion proteins in the serum were determined at different time
points, including 0 (pre-dose) 0.25, 0.5, 1, 2, 6, 24, 48, 96, 168,
216, 264 and 336 hours post dose-administration. At each time
point, 3 mice were sacrificed blood samples were collected into
separation tubes, which were incubated at room temperature for
30 minutes prior to centrifugation (to allow clotting). After
30 minutes, the tubes were immediately centrifuged (10 minutes
at 10,000rpm at room temperature) and serum was collected.
Levels of NKp30-Ig or NKp46D2-Ig fusion proteins in the serum
were analyzed using a standard ELISA assay.
Apoptosis assay
PC3/Luc or DU145 cells (50,000/ml) were incubated with 5, 10
or 50 mg/ml of NKp30-Ig, NKp46D2-Ig, NKp46D1-Ig or PBS
for 2 hours on ice. Cross -linking antibody (against human IgG1)
was than added at final concentrations that equal to 1/10 of the
amount of fusion protein added previously (0.5, 1 or 5 mg/ml).
Treatment with NK Receptors
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Cells were than incubated at 37uC for 48 hours and the
percentage of apoptotic cells was determined using a standard
Annexin V/PI analysis.
Macrophage-mediated killing assays
As effector cells we used peritoneal macrophages derived from
CD1 nude mice 5 days after Thioglycolate injection. Retrieved
macrophages were than activated for 2h with LPS (1mg/ml).
Radioactive labeled PC3/Luc or DU145 cells (1*104/well at flat
96-well plate) were incubated with the LPS-activated macrophages
at the indicated E:T ratios. Specific lysis was determined after
48 hours.
Results
Recognition of malignant primary human prostate
cancer by NKp30 and NKp46
NKp46 and NKp30 are constrictively expressed on the surface
of resting as well as activated NK cells and are dominantly
involved in the killing of various tumor cell lines in vitro. However,
since the cellular ligands of these receptors are still unknown, little
is known about their expression pattern and distribution in
different pathological settings.
Prostate cancer is the most frequently diagnosed solid tumor
among men in the United States and the second leading cause of
cancer deaths in western countries [22]. Unfortunately, there are
no effective therapies available today for the fatal hormone-
refractory stage of the disease. To test whether human prostate
tumors are recognized by the NCRs we stained the PC3/Luc and
DU145 cell lines with NKp30 and NKp46 proteins fused to
human IgG1. We have previously shown that the binding site of
NKp46 to various tumors is located at the membrane proximal
domain and the steam region of the receptor (D2) and that the
expression of D2 fused to human IgG (NKp46D2-Ig) enables
better recognition of target cells [13]. As shown in figure 1a and b,
both PC3/Luc and DU145 cells were specifically stained by
NKp30-Ig and NKp46D2-Ig, but not by the control CD99-Ig
(grey histograms), thus indicating the expression of ligands for
these two NK activating receptors on prostate tumor cell lines.
To extenuate our observations, we analyzed the expression of
ligands to NKp30 and NKp46 on primary prostatic adenocarci-
noma and benign prostatic hyperplasia (BPH) derived from
human patients. Formalin-fixed paraffin-embedded prostatic
cancers were stained with NKp30-Ig, NKp46D2-Ig or the control
fusion proteins (such as CD99-Ig). Figure 1c shows representative
examples of stained tissues and figure 1d summarizes the results
obtained from 9 adenocarcinoma and 8 benign prostate cancer
tissues. As shown, 7/9 and 5/9 prostate adenocarcinomas were
positively stained by NKp30-Ig and NKp46D2-Ig, respectively,
indicating the existence of ligands for NKp30 and NKp46 on the
malignant cells. The expression of these antigens encompassed 50–
95% of tumor cells with different degrees of intensities and showed
both intracellular and membranal distribution (Figure 1c, arrow at
the top left panel points to membrane staining). In contrast, all
BPH sections tested were negatively stained by NKp30-Ig or
NKp46D2-Ig, as in most cases less than 10% of the cells were
stained and the intensity was bellow 1. Importantly, neither the
adenocarcinomas nor the BPH sections were stained by the
control Ig fusion protein CD99-Ig (and other control proteins, data
not shown). These results demonstrate that similarly to prostate
cancer cell lines grown in culture, primary derived tumors
selectively express ligands for the NK lysis receptors NKp30 and
NKp46D2. Furthermore, the expression of these unknown ligands
is induced only at later stages of the disease in which
adenocarcinoma has already evolved.
NKp30-Ig inhibits the growth of the prostate cancer cell
line DU145 in vivo
Ig fusion proteins have been previously utilized as effective
therapeutic agents in clinical practice [23]. Here we demonstrate
that both NKp30-Ig and NKp46D2-Ig specifically bind human
tissues derived from prostate cancer patients, indicating the
presence of specific (although unknown) ligands (figure 1b and c).
To determine whether NKp30 and NKp46D2 fused to human
IgG1 could mediate effective anti tumor response in vivo, we
injected nude mice with the human prostate tumor line DU145.
Two weeks after injection, when the tumors became visible,
(defined as day 1 in figure 2) mice were treated with NKp30-Ig,
NKp46D2-Ig, control human IgG1 or PBS (note legend to figure 2
for treatment course and growth evaluation). In both control
groups receiving human IgG1 (n=10) or PBS (n=10), animals
demonstrated a rapid growth of tumors (figure 2). Similarly, the
NKp46D2-Ig treated mice (n=9) showed a gradual increase in
tumors size, indicating no therapeutic effect. In contrast, treatment
with NKp30-Ig (n=10) resulted in a remarkable suppression of
tumor development; as from the second administration of NKp30-
Ig (at day 7), tumors size remained constant for three weeks and
only a moderate progression was detected in the following days
(figure 2). Furthermore, in 5 out of 10 mice that were injected with
NKp30-Ig, the tumors disappeared after the second injection (day
7) and did not reappear even up to two months after the last
injection.
Treatment with NKp30-Ig reduces PC3/Luc tumor growth
in-vivo
Studying a complex biological process such as tumor growth
and therapy impact in-vivo requires a model that is both sensitive
and accurate enough to detect even subtle developments.
Recently, a new bioluminescence based imaging technology that
allows non-invasive detection of tumor cells in-vivo was reported
[14,24]. This strategy relies on the engraftment of human cancers
that stably express a reporter gene, such as luciferase (Luc), into
mice. Expression of luciferase enables in-vivo monitoring of the
relative size and distribution of the tumors and can therefore also
detect metastatic development. Furthermore, this system is highly
sensitive and reliable in detection of minor tumors that are difficult
or even impossible to sense in other methods such as direct tumor
size measurements or FACS analysis of tumor extracts [24]. For
this reason, we used the human prostate cancer cell line PC3
labeled by stable expression of luciferase gene (PC3/luc) that was
previously applied in other similar in-vivo models [14].
To monitor the effect of NKp30-Ig and NKp46D2-Ig fusion
proteins on the progression of PC3/luc prostate cancer cell line in-
vivo, we injected male nude mice with PC3/luc cells. Three weeks
after injection (designated as ‘start point’), tumor growth was
assessed by the CCCD camera and those mice expressing tumors
that were large enough for transmitting an integrated signal
intensity of 100 photon counts and above, were chosen for further
treatment with NKp30-Ig (n=16), NKp46D2-Ig (n=9) or with
PBS as control (n=8). The treatment included an i.p. injection of
PBS or 4mg/kg body weight of the relevant fusion protein, given
every other day for a month. In the end of the treatment period
(designated as ‘end point’), tumor size was evaluated again in the
CCCD camera.
As shown in figure 3a and summarized in figure 4b, treatment
of mice with NKp30-Ig had a dramatic effect on tumor growth.
Treatment with NK Receptors
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While in the control group (figure 3c and 4), rapid increase in
tumor size was observed in almost all the animals (87.5%),
NKp30-Ig-treatement led to a substantial reduction in tumor
progression; in 50% of the mice treated with NKp30-Ig the tumor
was drastically reduced to 20% or bellow of its original size
(regarded as ‘efficient treatment’), 25% showed partial effect while
25% did not respond and developed progressive tumors.
Moreover, in those mice in which efficient treatment was obtained,
no relapse was observed even 3 month after the last NKp30-Ig
administration. Importantly, NKp30-Ig therapeutic effect was not
dependent on the original size of the tumor, as responsiveness or
unresponsiveness did not correlate with the initial signal detected
from the tumor, as measured in the ‘start point’ (indicated in
numbers above each column).
NKp30-Ig treatment significantly suppressed growth of both
DU145 and PC3/Luc, yet with a more prominent effect on PC3/
Luc (figures 2–4). This could not be attributed to differences in
ligand expression (figure 1a) and could reflect the enhanced
progressive growth of DU145 compared to PC3/Luc. In contrast
to NKp30-Ig and in agreement with the results presented above
(figure 2), NKp46D2-Ig treatment had only a marginal effect
(figure 3b and 4); 66.6% of the mice treated with NKp46D2-Ig
showed progressive tumor growth, while 22.2% and 11.1% were
partially cured or effectively treated, respectively.
Figure 4a shows an illustration of one representative mouse
from each treatment group. In most cases no metastases were
observed. The tumor measurements described above (figure 3)
represent the entire tumor mass detected in each animal.
Figure 1. Expression of NCRs ligands on human prostate cancer. (a,b) NKp30-Ig and NKp46D2-Ig specifically bind to human prostate cell
lines. PC3/Luc (a) and DU145 (b) cell lines were stained with NKp30-Ig, NKp46D2-Ig or control CD99-Ig, followed by PE-conjugated mouse anti-human
IgG1 antibody. Grey histograms represent the background staining by the control CD99-Ig fusion protein and the black empty histograms represent
the staining by either NKp30-Ig or NKp46D2-Ig, as indicated in the top of each histogram. This figure represents one experiment out of three
performed. (c) Immunohistochemical staining of primary human prostate adenocarcinoma and benign prostate hyperplasia (BPH) by NKp30-Ig and
NKp46D2-Ig. Cuts from formalin-fixed and paraffin-embedded human prostate adenocarcinoma (upper panel) and BPH (lower panel) were antigen-
retrieved by microwave-citrate treatment. Slides were then stained with NKp30-Ig, negative control CD99-Ig or NKp46D2-Ig, followed by biotinylated-
goat-anti-human-Fc and avidin-biotin HRP complex. Substrate for HRP was AEC (red color) and slides were counter-stained with Hematoxylin. Figure
shows a representative staining at X400 magnification. Arrow in NKp30-Ig staining of adenocarcinoma (top left panel) points to a representative
membrane staining. Staining intensity for top left and top right panels is considered as 2 (see Methods). (d) Expression of NKp30 and NKp46 ligands is
abundant on malignant prostate tumors. Cuts from different patients suffering from benign (n=8) or malignant (n= 9) prostate tumors were
prepared and stained as above. Staining was performed in triplicates. Analysis of staining intensity (0-3) and percentage of stained tumor cells was
performed by two pathologists. Positive staining was defined when staining intensity was above 1 and encompassed at least 50% of the cells, as
described in ‘material and methods’.
doi:10.1371/journal.pone.0002150.g001
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These results clearly demonstrate the therapeutic potential of
NKp30-Ig fusion protein for human prostate cancer treatment in
vivo.
Pharmacokinetics of NKp30-Ig and NKp46D2-Ig
Taken together, our results indicate that NKp30-Ig, but not
NKp46D2-Ig, can suppress tumor growth in vivo. This selective
effect was surprising since both NKp30-Ig and NKp46D2-Ig
similarly bind to PC3/Luc, DU145 (figure 1a and b) and human
prostate cancer specimens in vitro (figure 1c). Thus, the differences
between the therapeutic potential of NKp46D2-Ig and NKp30-Ig
must result from other characteristics of the proteins that influence
the efficiency of treatment.
One of the most important factors in cancer therapy is the t1/2
of the therapeutic agent. In order to mediate a significant anti-
tumor effect the fusion proteins must be able to reach the serum
and remain stable for several hours.
To estimate the relative stability of the fusion proteins in vivo,
mice were given a single dose (5mg/kg body weight) of either
NKp30-Ig or NKp46D2-Ig and then monitored for specific
protein levels in the serum every few hours for 14 days. The
maximal level of proteins measured in the serum was similar for
both NKp46D2-Ig and NKp30-Ig (figure 5a and b). However,
clear differences were observed in the kinetics and stability of the
two fusion proteins; high levels of NKp46D2-Ig were identified in
the serum after 1 hour from injection, albeit decreased rapidly in
the blood and within 2 hours almost 50% of the protein was
degraded. Moreover, after 24 hours, only small traces of
NKp46D2-Ig were found (figure 5b). In contrast, highest levels
of NKp30-Ig were detected in the serum already 30 minutes after
injection and were maintained for almost 2 days, decreasing only
after 120 hours (figure 1a). These observations demonstrate the
relative stability of NKp30-Ig in vivo and may explain, at least
partially, the failure of NKp46D2-Ig to produce a therapeutic
effect.
NKp30-Ig enhances macrophages-mediated cytotoxicity
against tumor cells in vitro
Several mechanisms have been proposed for the ability of tumor
antibodies to mediate their effect in vivo. One possible way by
which such antibodies can inhibit tumor growth is by binding to
surface receptors that are involved in cell cycle regulation [25]. We
therefore first tested whether binding of NKp30-Ig to its unknown
tumor ligands can induce direct apoptosis or growth arrest of
tumor cells in culture. PC3/luc and DU145 cells were incubated
with increasing concentrations of NKp30-Ig, NKp46D2-Ig or
control Ig fusion protein for 48 hours in the presence of a cross
linking antibody. Following treatment, the percentage of apoptotic
cells was determined by Annexin V and propidium iodide (PI)
staining. Incubation of either PC3/luc or DU145 cells with the
various fusion proteins had no effect on the apoptosis rates
(figure 6a and b) as the mean spontaneous apoptosis of PC3/luc
and DU145 cells (around 25% and 8%, respectively) remained
similar and was not affected by any of the treatments. In addition,
no cell cycle arrest was observed, as evaluated by thymidine
incorporation assays (data not shown). Similar results were
obtained following incubation for 24 h or 72 h (data not shown).
Since the tumor cells did not demonstrate any intrinsic
sensitivity to NKp30-Ig in vitro, we next tested the capacity of
NKp30-Ig to induce effector-mediated killing of tumor cells.
Macrophages have been previously implicated as major players in
antibody-dependent tumor control in vivo [26,27]. To evaluate the
ability of NKp30-Ig to enhance macrophages-mediated lysis of
tumor cells, mice were first injected (i.p.) with thioglycolate in
order to cause a local non-pathogenic inflammation and recruit
large numbers of macrophages into the peritoneum cavity. Five
days later, mice were sacrificed and macrophages were isolated.
To enhance the cytolytic activity, macrophages were activated in
culture with LPS and than tested for the ability to lyse PC3/luc and
DU145 cells coated with NKp30-Ig or control Ig fusion protein, at
various E:T ratios. Little or no killing was observed when cells
were coated with a control Ig fusion protein, even at the highest
E:T ratios tested (50:1 and 100:1 for PC3/luc and DU145 cells,
respectively, figure 6c and d). In contrast, pre-incubation of both
PC3/luc and DU145 cells with NKp30-Ig resulted in an enhanced
lysis of the targets. It should be noted that, although higher E:T
rations were required in order to efficiently lyse the DU145 cells,
as compared with PC3/luc cells, both targets were sensitive to
NKp30-Ig mediated killing by activated macrophages. We did not
observe any effect of NKp30-Ig on the ability of freshly isolated
NK cells or complement components to kill PC3/luc and DU145
cells in vitro (data not shown). Finally, histological examination of
the DU145 tumor tissue revealed filtrates of immune cells
including macrophages (Fig. 6c, pointed by black arrows), further
indicating a possible involvement of macrophages in the clearance
of prostate xenographts. Thus, the inhibition of tumor growth in
vivo by NKp30-Ig may depend, at least partially, on a macrophages
mediated response.
Discussion
A key factor in effective therapy is the specificity of the
therapeutic agent. Cancer immunotherapy attempts to exploit the
highly specific nature of the immune system to treat malignancy by
using humanized monoclonal antibodies or Ig fusion proteins that
selectively bind to tumor antigens. However, finding a suitable
antigen is a critical step that has often proved to be difficult,
Figure 2. NKp30-Ig treatment reduces growth of prostate cell
line DU145 in vivo. Male nude mice injected with the human prostate
tumor line DU145 (46106), were treated with NKp30-Ig (n= 10),
NKp46D2-Ig (n= 9), control human IgG1 (n=10), or PBS (n=10). Day
1 is defined at two weeks post-injection when tumors became visible.
Treatments were administered 5 times (days 1, 7, 15, 25 and 34, marked
by arrows) and included an initial larger dose of the proteins (20 mg/kg)
followed by lower doses (10 mg/kg). Tumor progression was evaluated
every three days by measuring the diameter of the tumors. The graphs
show the average diameter (mm) of the tumors in each group
measured in days 1–45.
doi:10.1371/journal.pone.0002150.g002
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especially in the case of solid tumors. Importantly, while the
adaptive immune response successfully produces tumor specific
antibodies and CTLs that may be harnessed for clinical use, these
are often limited to a specific type of cancer and are therefore
suitable for only a minor fraction of the patients. Thus, the
identification of tumor specific markers with a broader specificity is
of great importance.
Since innate immune mechanisms are evolutionary designed to
respond to a broad spectrum of pathological conditions, including
cancer, applying the molecular mechanisms that mediate this
recognition may help to develop new anti-tumor medicines. The
natural cytotoxic receptors (NCRs), which are expressed on NK
cells, are an attractive example of such proteins with specificity for
tumor ligands commonly expressed on multiple types of
transformed cells. In light of the restricted fashion by which these
ligands are primarily confined to tumors, these molecules may
represent an excellent target for cancer therapy. We published that
tumor-associated heparan sulfate molecules are involved as co-
ligands for NCRs [28–31]. However, since the identity of the
heparan sulfate epitopes and of the other NCRs’ ligands is still
unknown, direct targeting is impossible. In this study we suggest an
alternative approach; by generating NCR-Ig fusion proteins we
allow the NK receptors to bind to their preferred (and mostly
unknown) tumor ligands and to selectively recruit, via the Ig
domain, effector mechanisms against the malignant cells. Whether
NKp30-Ig therapy might affect healthy human cells remains to be
studied. Ligands to NCRs may be expressed primarily as a
consequence of cellular stress, activation, viral infection, or tumor
transformation [32,33], therefore not by healthy cells; yet
immature DC were reported to express ligands to NKp30 [34].
We demonstrate the therapeutic potential of this approach in
two in vivo models of human prostate cancer; PC3/Luc and DU145
cell lines. We show that in both models a significant inhibition of
tumor growth was achieved when animals were treated with
NKp30-Ig fusion protein. Moreover, in 50% of the mice injected
with either PC3/Luc or DU145 cell lines, treatment resulted in
complete growth arrest of the tumor with no relapse. The
emergence of ligand-negative tumor cells, following therapy-
mediated selective pressure is a frequent phenomenon in tumor
therapy. This could account for the unresponsiveness to treatment
observed in fraction of the mice. We harvested tumor cells from
two mice with progressive tumor growth: one treated with NKp30-
Figure 3. Treatment with NKp30-Ig reduces PC3/Luc tumor growth.Male nude mice were injected with PC3/luc tumor cells (156106) into the
SC left flanks. Three weeks after tumor implantation, mice were injected (i.p.) every second day over a period of one month with 4mg/kg of NKp30-Ig
(n=16) (a), NKp46D2-Ig (n=9) (b) or PBS (n= 8) (c). Tumor progression was monitored by measuring light emission from each individual mouse in the
initiation (‘start point’) and in the end (‘end point’) of the treatment period. Y-axes represent the relative (in percentage) changes in tumor size after
treatment, as calculated from the integrated light emission measured in each time point (indicated numbers above columns). Shrinkage of the tumor
by 20% or below its original size was referred as ‘efficient treatment’. This figure is a summary of two experiments and includes all the mice that were
tested.
doi:10.1371/journal.pone.0002150.g003
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Ig-and one treated with NKp46D2-Ig. Staining of the tumor cells
with NKp30-Ig and NKp46D2-Ig revealed down-regulation of the
ligand specific for the treatment (data not shown). Thus, tumor-
escape variants could emerge following NCR-Ig treatment but
more mice should be studied to accurately define this phenom-
enon.
The in vivo results demonstrated here indicate a potential novel
therapeutic approach. Several ways should be considered in order
to improve its effect. Importantly, since NKp30-Ig is not efficiently
internalized upon binding to tumor cells (data not shown), its
coupling to toxins is not likely to increase its anti-tumor abilities.
However, alternative strategies may be considered, including
arming the NKp30-Ig with radionuclides, attaching NKp30-Ig to
the surface of liposomes for selective tumor targeting of
chemotherapy toxins or even DNA for gene therapy, or using
NKp30 as the tumor-specific epitope of a bi-specific antibody [20].
In addition, combined treatment with both NKp30-Ig and
conventional chemotherapy should be tested. This strategy is of
particular interest since clinical studies of antibody-based immu-
notherapy have clearly shown that in most cases, the best response
is obtained when antibody treatment is combined with standard
chemotherapy. For example, administration of Rituximad togeth-
er with chemotherapy increased the response rates from 50% to
95% [35,36]. Similar synergistic effects with no increase in toxicity
were also documented for other anti-tumor antibodies, such as
Herceptin and Erbitux, [37,38]. The exact molecular events by
which antibody-based immunotherapies exert their therapeutic
effect are not always entirely understood and it is believed that
multiple mechanisms are involved. However, both in vitro and in
vivo studies indicate that antibody-dependent-cell-mediated cyto-
toxicity (ADCC) is the predominant mode by which an anti-tumor
response is achieved [27]. The most conclusive evidence for the
importance of an ADCC response in antibody-based immuno-
therapies comes from in vivo studies of knockout mice in which the
activating Fc receptors were impaired [26,39]. These studies
clearly demonstrated that the therapeutic potency of two clinically
effective mAbs, Herceptin and Rituxan, greatly depends on the
Figure 4. Summary of fusion protein treatment. (a) Visualization
of tumor progression and distribution in vivo. The figure shows an
image visualization of one representative animal of each treatment. The
scale on the right of each figure describes the color map of the photon
count. The integrated light emission (‘I’) is indicated in the left of each
photo. (b) Summary of treatment effect. Table describes the overall
effect of treatments, as shown in details in figure 3.
doi:10.1371/journal.pone.0002150.g004
Figure 5. Pharmacokinetics of NKp30-Ig and NKp46D2-Ig
fusion proteins in vivo. Mice were injected i.p. with one dose
(5mg/kg) of NKp30-Ig (a) or NKp46D2-Ig (b). Serum sample were
collected (at 0, 0.5, 1, 2, 6, 25, 48, 120, 168, 264 and 312 hours after
injection) and levels of NKp30-Ig or NKp46D2-Ig were determined in a
standard ELISA assay. Figure shows the average amount of fusion
proteins detected in the serum of three mice, measure at each time
point. Error bars represent mean6s.d of triplicates.
doi:10.1371/journal.pone.0002150.g005
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expression of activating Fc receptors on immune cells. In
agreement, mice deficient in the FccRIIB inhibitory Fc receptor
showed an enhanced ADCC response [26,39]. Furthermore,
monocytes and macrophages were suggested to function as the
dominant effector cells in the antibody-mediated protection in vivo
[26]. Our in vitro data suggest that NKp30-Ig may also mediate its
therapeutic effect via a similar mechanism enhancing a macro-
phage-dependent ADCC response. The fact that the binding of
NKp30-Ig to tumor cells in vitro is stable and does not induce
internalization of its unknown ligand (data not shown) may
increase the efficiency of an ADCC response.
While macrophages-mediated ADCC response may be an
important way by which NKp30-Ig suppresses tumor growth in
vivo, other additional mechanisms may also contribute to this
effect. In this regard it should be noted that the inability of
NKp30-Ig to produce any detectable changes in the cell cycle of
PC3/Luc and DU145 cell lines in vitro may not necessarily be the
case in the more complex environment in vivo. The absence of
basic information regarding the nature of the tumor molecules
that are recognized as ligands by the NCRs complicates this issue
and prevents its direct examination. However, the abundant
expression of potential NCRs ligands on clinically derived tumor
samples suggests that in vivo these ligands are maintained, despite
the probable selective pressure exerted by NK cells. Thus, it is
possible to speculate that the NCRs ligands may be vital for the
survival and progression of transformed cells. Binding of the Ig
fusion proteins to these ligands may therefore contribute to
tumor growth arrest by directly interfering with the activation of
these molecules, and consequently suppress the tumorigenic
process in vivo.
While both NKp30-Ig and NKp46D2-Ig showed specific and
similar levels of binding to PC3/Luc and DU145 cell lines in vitro,
Figure 6. Mechanism of NKp30-Ig mediated tumor regression. (a,b) NKp30-Ig does not induce apoptosis in tumor cells. PC3/luc (a) or DU145
(b) cells were incubated with increasing concentrations of NKp30-Ig, NKp46D2-Ig, control Ig or PBS in the presence of a cross-linking antibody. After
48 hours, the percentage of apoptotic cells was determined by Annexin V and PI staining. The figure shows one out of three experiments performed.
(c,d) NKp30-Ig can mediate tumor opsonization by macrophages. Radioactive labeled PC3/Luc (c) or DU145 (d) cells were incubated with LPS-
activated macrophages at the indicated E:T ratios. Specific lysis was determined after 48 hours. Error bars represent mean6s.d of triplicates. Figure
represents one out of three experiments performed. (e) Infiltration of macrophages to the tumor tissue. Human prostate tumors (DU145) grown in
nude mice were fixed in 10% buffered formalin. Paraffin-embedded sections were stained in Hematoxylin and Eosin. The arrows indicate tumor
associated- macrophages (X380). This figure represents one out of 5 sections tested.
doi:10.1371/journal.pone.0002150.g006
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treatment of mice with NKp46D2-Ig did not induce any therapeutic
effect and no inhibition of tumor growth was observed in either the
PC3/Luc or the DU145 xenografts. This observation may be
explained by the relatively short half-life of the NKp46D2-Ig fusion
protein.
Prostate cancer is one of the most prevalent cancers in males.
More then 230,000 persons are diagnosed every year in the US.
The progression of the disease includes a transition from an
androgen-dependent stage, in which the cancer is organ-confined
and still curable, to an androgen-independent stage, in which the
tumor metastasizes to other organs and in many cases leads to
death [22]. An accurate diagnosis of the disease stage is therefore
of great importance and has direct implications on the treatment
strategy. The early diagnosis usually relies upon the symptoms of
the patient, the digital rectal examination (DRE) and the prostate
specific antigen (PSA) level [40]. Unfortunately, none of these tests
are accurate and reliable enough to clearly determine the stage of
the disease and in order to gain a conclusive diagnosis a TRUS
guided biopsy is required [41]. However, despite the fact that the
biopsies are repetitively taken (at least 6 times from each patient),
there is always the problematic risk of missing those tissues in
which the most advanced stage of the tumor has been established.
It is therefore critical to develop additional tests that would
provide supplementary information and allow consistent distin-
guish between idle and aggressive prostate cancer. The ability of
NKp30-Ig to effectively target prostate cancer in vivo may
therefore be further applied as a diagnostic tool used as a marker
in magnetic resonance spectroscopy (MRS) test. Previous
attempts to exploit the MRS technique for prostate cancer
diagnosis were proved fruitful [42]. Since NKp30-Ig selectively
binds prostate adenocarcinoma, but not BPH, we hypothesize
that it may provide additional valuable information that would
help to distinguish between these two common pathological
conditions.
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